Bristol Myers Squibb delivered better than expected fourth quarter earnings, but Eliquis missed expectations while Cobenfy ...

The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.

Huzhou FFD Power will localize BMS, EMS, and C&I BESS cabinet production in Europe; initial cabinet platforms: 261 ...

The FDA has started a priority review of iberdomide as an add-on to Johnson & Johnson and Genmab's anti-CD38 antibody Darzalex (daratumumab) and dexamethasone, a standard regimen for relapsed or ...

Bristol Myers Squibb said in its fourth-quarter results update this morning that it will double down on an ongoing cost-cutting programme announced last year. The company still intends to slash $1.5 ...

The FDA has accepted Bristol Myers Squibb (BMS)’s New Drug Application (NDA) for iberdomide for relapsed or refractory ...

Q4 2025 Management View Sachin Lawande, President and CEO, stated that "overall, we delivered a strong performance in 2025 despite several industry challenges." Net sales for the year were reported at ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

Supreme Court declines to stay Zydus Lifesciences' launch of biosimilar nivolumab, asks BMS to seek interim relief before ...